Inhibitory effects of a novel cationic dodecapeptide [CL(14-25)] derived from cyanate lyase of rice on endotoxic activities of LPSs from Escherichia coli and periodontopathic Aggregatibacter actinomycetemcomitans

Microb Pathog. 2016 May:94:2-11. doi: 10.1016/j.micpath.2015.08.011. Epub 2015 Aug 28.

Abstract

Objective: CL(14-25), a dodecapeptide of cyanate lyase from rice, is a novel cationic α-helical antimicrobial peptide. In this study, we examined inhibitory ability of CL(14-25) against endotoxic activities of lipopolysaccharides (LPSs) from Escherichia coli and periodontal pathogenic Aggregatibacter actinomycetemcomitans.

Methods: Endotoxin-neutralizing activity of CL(14-25) was evaluated by inhibition to induction of cytokine and nitric oxide in human aortic endothelial cells (HAECs) and RAW264 mouse macrophage cells, respectively. Protective effect of CL(14-25) was determined in mice against lethal toxicity of LPS.

Results: IL-6 in HAECs was induced by stimulation with LPS preparations of A. actinomycetemcomitans and E. coli tested in this study, and addition of CL(14-25) to the medium caused inhibition of their induction in a dose-dependent manner. CL(14-25) inhibited NO induction in RAW264 cells by a smooth type LPS of E. coli O55:B5 and an Rc type LPS of E. coli J5 as well as lipid A of E. coli R515 in a dose-dependent manner. Simultaneous injection of E. coli O55:B5 LPS and CL(14-25) in BALB/c mice resulted in prevention of lethal toxicity of the former. The results of a Limulus amebocyte lysate assay and surface plasmon resonance analysis of interaction between CL(14-25) and E. coli LPS or lipid A showed that CL(14-25) specifically binds to a lipid A moiety of LPS.

Conclusion: The results of present study suggest that CL(14-25) has a potential to be used as a nutraceutical agent for periodontal therapy.

Keywords: Antimicrobial peptides; Inflammatory mediator; Lipopolysaccharide.

MeSH terms

  • Aggregatibacter actinomycetemcomitans / chemistry
  • Aggregatibacter actinomycetemcomitans / metabolism*
  • Animals
  • Carbon-Nitrogen Lyases / chemistry*
  • Cytokines / biosynthesis
  • Cytokines / metabolism
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Endothelial Cells / drug effects
  • Escherichia coli / chemistry
  • Escherichia coli / metabolism*
  • Humans
  • Interleukin-6 / biosynthesis
  • Lipid A / antagonists & inhibitors
  • Lipid A / chemistry
  • Lipid A / toxicity
  • Lipopolysaccharides / antagonists & inhibitors*
  • Lipopolysaccharides / chemistry
  • Lipopolysaccharides / toxicity
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Nitric Oxide / biosynthesis
  • Nitric Oxide / metabolism
  • Oryza / enzymology
  • Peptide Fragments / chemistry
  • Peptide Fragments / pharmacology*
  • RAW 264.7 Cells

Substances

  • CL(14-25)
  • Cytokines
  • Interleukin-6
  • Lipid A
  • Lipopolysaccharides
  • Peptide Fragments
  • Nitric Oxide
  • cyanate hydrolase
  • Carbon-Nitrogen Lyases